期刊文献+

肝癌靶向药物治疗的研究进展 被引量:8

Research Progress in Targeted Therapy for Hepatocellular Carcinoma
原文传递
导出
摘要 肝癌的分子靶向治疗具有较好的分子选择性,能高效并选择性地杀伤肿瘤细胞,减少对正常组织的损伤。目前肝癌的靶向药物治疗主要有以下几种:肝细胞生长因子及其受体抑制剂、多靶点激酶抑制剂、抗血管内皮生长因子(VEGF)药物、表皮生长因子受体抑制剂、DNA甲基化抑制剂、环氧化酶-2抑制剂、Nucler factor-kappa B(NF-κB)路径靶向药物、细胞周期控制药物等。全文对肝癌靶向药物治疗的研究进展作一综述。
机构地区 浙江省肿瘤医院
出处 《肿瘤学杂志》 CAS 2009年第2期156-161,共6页 Journal of Chinese Oncology
  • 相关文献

参考文献3

二级参考文献37

  • 1De Yun Feng,Hui Zheng,Yi Tan,Rui Xue Cheng Department of Pathology, Hunan Medical University, Changsha 410078, Hunan Province, China New England Biolab, MA, USA.Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance[J].World Journal of Gastroenterology,2001,7(1):33-36. 被引量:76
  • 2何怡,王东,张沁宏,卿毅,杨宇馨.EGFR抑制剂吉非替尼对肝癌细胞增殖和凋亡的影响[J].第三军医大学学报,2006,28(2):125-128. 被引量:13
  • 3[1]Burroughs A,Hochhauser D,Meyer T.Systemic treatment and liver transplantation for hepatocellular carcinoma:two ends of the therapeutic spectrum.Lancet Oncol 2004; 5:409-418
  • 4[2]Llovet JM,Burroughs A,Bruix J.Hepatocellular carcinoma.Lancet 2003; 362:1907-1917
  • 5[3]Torimura T,Sata M,Ueno T,Kin M,Tsuji R,Suzaku K,Hashimoto O,Sugawara H,Tanikawa K.Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma.Hum Pathol 1998; 29:986-991
  • 6[4]Yamaguchi R,Yano H,Iemura A,Ogasawara S,Haramaki M,Kojiro M.Expression of vascular endothelial growth factor in human hepatocellular carcinoma.Hepatology 1998; 28:68-77
  • 7[5]Kenyon BM,Browne F,D'Amato RJ.Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization.Exp Eye Res 1997; 64:971-978
  • 8[6]Peuckmann V,Fisch M,Bruera E.Potential novel uses of thalidomide:focus on palliative care.Drugs 2000; 60:273-292
  • 9[7]Little RF,Wyvill KM,Pluda JM,Welles L,Marshall V,Figg WD,Newcomb FM,Tosato G,Feigal E,Steinberg SM,Whitby D,Goedert JJ,Yarchoan R.Activity of thalidomide in AIDS-related Kaposi's sarcoma.J Clin Oncol 2000; 18:2593-2602
  • 10[8]Patterson SG,Fishman M,Kish J,Ewbank D,Defelice J,Rago R.Thalidomide plus daily oral dexamethasone for metastatic hormone refractory prostate cancer (HRPC) in patients previously treated with cytotoxic chemothertapy.Proc Am Soc Clin Oncol 2003; 22:444,abstract:1783

共引文献38

同被引文献123

引证文献8

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部